Prosecution Insights
Last updated: May 29, 2026
Application No. 18/031,294

ADENO-ASSOCIATED VIRUS VIRIONS AND METHODS OF USE THEREOF

Non-Final OA §102§112§OTHER
Filed
Apr 11, 2023
Priority
Oct 21, 2020 — provisional 63/094,820 +1 more
Examiner
HILL, MYRON G
Art Unit
1671
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Regents of the University of California
OA Round
1 (Non-Final)
66%
Grant Probability
Favorable
1-2
OA Rounds
1m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
459 granted / 690 resolved
+6.5% vs TC avg
Strong +20% interview lift
Without
With
+19.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
30 currently pending
Career history
724
Total Applications
across all art units

Statute-Specific Performance

§101
2.6%
-37.4% vs TC avg
§103
41.7%
+1.7% vs TC avg
§102
4.1%
-35.9% vs TC avg
§112
16.4%
-23.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 690 resolved cases

Office Action

§102 §112 §OTHER
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of Group VI (claims 31 and new claims 33-37) in the reply filed on 1/30/26 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 1, 8-12, 15-16, 19-22, 24, 26, and 29-30 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected inventions, there being no allowable generic or linking claim. Applicant is reminded to amend the withdrawn claims as needed to facilitate rejoinder. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 36-37 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. The mutations are more than allowed by claim 31 and thus the claims include sequences not part of claim 31. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 31 is/are rejected under 35 U.S.C. 102a1 as being anticipated by Ojala et al. (WO2016154344). Ojala et al.teach SEQ ID# 16 that has the same base sequence and has the changes as listed in the claim “[0005] Aspects of the present disclosure include an rAAV virion containing: a) a variant AAV capsid protein, wherein the variant AAV capsid protein includes an amino acid sequence having at least 95% amino acid sequence identity to the sequence set forth in SEQ ID NO: 16, wherein the amino acids at positions 264, 448, 459, 470, 495, 533, 547, 555, 557, 561, 563, 593, 596, 661, 662, 664, 718 and 723 are A, A, N, S, S, D, E, A, E, L, N, A, A, A, T, T, N and S, respectively; Q, S, N, A, S, E, Q, T, D, M, S, Q, T, A, V, S, S and S, respectively; or A, A, T, S, T, D, Q, A, D, I, N, A, T, T, V, S, S and T, respectively” (para 5, SEQ ID# 16). Thus, Ojala et al. anticipate the claim. Claim(s) 31 and 33 is/are rejected under 35 U.S.C. 102a1 as being anticipated by Kim et al. (11364308). Kim et al. teach SEQ ID # 59 that is 98% identical to SEQ ID# 53 and has the positions are required by claim 31. See comparison sheet. The prior art sequence has changes at positions 266, 664, and 717 that are not limited by claim 31. Positions 448, 459, 551, 596, 593, 718, and 719 have residues that are in the scope of claim 31 limitations. Thus, Kim et al. anticipate the claimed invention. Allowable Subject Matter Claims 34-35 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MYRON G HILL whose telephone number is (571)272-0901. The examiner can normally be reached Mon-Fri. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Allen can be reached at 571-270-3497. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. MYRON G. HILL Examiner Art Unit 1671 /M.G.H/Examiner, Art Unit 1671 /Shanon A. Foley/Primary Examiner, Art Unit 1671
Read full office action

Prosecution Timeline

Apr 11, 2023
Application Filed
Apr 02, 2026
Non-Final Rejection mailed — §102, §112, §OTHER (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12629413
Utilizing Vaccines to Treat Cancer and Enhance the Success Rate of Cancer Immunotherapy
5y 4m to grant Granted May 19, 2026
Patent 12630890
Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
3y 5m to grant Granted May 19, 2026
Patent 12606803
METHODS FOR GROWING AFRICAN SWINE FEVER VIRUS IN FETAL PORCINE LUNG ALVEOLAR MACROPHAGE CELLS
4y 3m to grant Granted Apr 21, 2026
Patent 12605440
MICRONEEDLE CONTAINING INFLUENZA VACCINE AND INFLUENZA VACCINE PATCH CONTAINING THE SAME
3y 4m to grant Granted Apr 21, 2026
Patent 12594312
BACTERIOPHAGE COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTION
4y 11m to grant Granted Apr 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
66%
Grant Probability
86%
With Interview (+19.8%)
3y 2m (~1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 690 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month